Evaluation of Spironolactone Efficacy in Patient With Rheumatoid Arthritis (RA)
Status:
Not yet recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
Evaluation of spironolactone, a well-known cardiological treatment, in patients with
rheumatoid arthritis (RA).
The hypothesis is that spironolactone, through its anti-inflammatory and anti-fibrosis
actions, decreases RA's activity. The primary objective is to assess the efficacy of
spironolactone on RA activity by evaluating the proportion of patients achieving DAS28-CRP <
3.2 at 3 months (comparison between spironolactone and placebo arms). CRP (C reactive
protein)